• METTL16-SENP3-LTF Axis Regulates Ferroptosis in HCC Progress

  2026-04-20

  Wang et al. identify a novel METTL16-SENP3-LTF signaling axis that suppresses ferroptosis and facilitates hepatocellular carcinoma (HCC) progression by modulating iron metabolism and m6A RNA modification. These findings highlight a potential therapeutic target for sensitizing HCC cells to ferroptosis-based interventions.

• CPI-613: Applied Strategies in Tumor Cell Metabolism Researc

  2026-04-19

  CPI-613 (6,8-bis(benzylsulfanyl)octanoic acid) empowers researchers to dissect mitochondrial metabolism and apoptosis in cancer models with precision. This guide reveals optimized workflows, key troubleshooting insights, and actionable protocol parameters for maximizing experimental success in apoptosis assays and tumor cell metabolism studies.

• ML385 and NRF2 Inhibition: Precision Tools for Redox Biology

  2026-04-18

  Explore how ML385, a selective NRF2 inhibitor, empowers advanced research into redox signaling, ferroptosis, and therapeutic resistance. Discover unique assay insights and practical protocol guidance informed by the latest scientific findings.

• Lanabecestat (AZD3293): BACE1 Inhibitor for Alzheimer’s Rese

  2026-04-17

  Lanabecestat (AZD3293) is a potent, selective, orally active BACE1 inhibitor widely used in Alzheimer’s disease research. Its blood-brain barrier penetration and sub-nanomolar affinity enable targeted amyloid-beta reduction without impacting synaptic transmission at moderate exposures.

• I-BET151 (GSK1210151A): BET Inhibition and Disulfidptosis in

  2026-04-16

  Explore how I-BET151 (GSK1210151A) enables innovative interrogation of disulfidptosis and super-enhancer-driven transcription in cancer biology. This article offers a nuanced, assay-focused perspective that extends beyond standard BET inhibitor applications.

• LY294002: Precision PI3K Inhibition for Advanced Cell Signal

  2026-04-15

  LY294002 stands apart as a robust, cell-permeable PI3K/Akt/mTOR signaling pathway inhibitor, enabling researchers to dissect cancer, fibrosis, and autophagy pathways with unmatched specificity. Its reversible action and dual targeting of class I PI3K isoforms and BET bromodomain proteins empower versatile experimental designs and troubleshooting flexibility.

• PNU 74654: Wnt Signaling Pathway Inhibitor for Research Use

  2026-04-14

  PNU 74654 is a high-purity, small molecule Wnt signaling pathway inhibitor validated for precise modulation of Wnt/β-catenin signaling. It is crucial for investigating cell proliferation and differentiation in cancer and stem cell models. This article details its mechanism, evidence base, and critical workflow parameters.

• Prochlorperazine-Induced Hemidystonia as an Acute Stroke Mim

  2026-04-13

  This article analyzes a reference study reporting the first documented case of prochlorperazine-induced hemidystonia presenting as an acute stroke mimic in a pregnant patient. The findings underscore the diagnostic challenges in emergency neurology and highlight the critical importance of differentiating true ischemic stroke from mimics, particularly in the context of time-sensitive interventions.

• DIDS: Advanced Strategies for Modulating Metastatic Cell Fat

  2026-04-12

  Explore the multifaceted applications of DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid) in dissecting chloride channel function, tumor metastasis, and neuroprotection. This article uniquely connects mechanistic insights with protocol optimization for next-generation cancer and neuroscience research.

• FLT3-TAZ Signaling Drives Drug Resistance in BP-CML: Insight

  2026-04-12

  Shin et al. (2023) reveal that aberrant FLT3-TAZ signaling defines a high-risk, drug-resistant subgroup in blast phase chronic myeloid leukemia (BP-CML), independent of BCR::ABL1 mutations. The study demonstrates that targeting FLT3—using inhibitors—restores sensitivity to tyrosine kinase inhibitors and suggests novel therapeutic strategies for overcoming resistance.

• PPM-18 for iNOS Inhibition: Optimizing Inflammation Research

  2026-04-11

  PPM-18 (N-(1,4-dihydro-1,4-dioxo-2-naphthalenyl)-benzamide) enables precise, reproducible inhibition of iNOS via NF-κB pathway modulation, advancing both in vitro and in vivo inflammation studies. This guide delivers actionable protocol enhancements, troubleshooting insights, and bridges the latest cardiovascular signaling research into translational sepsis workflows.

• Dovitinib (TKI-258): Applied Workflows in Cancer Research

  2026-04-11

  Dovitinib (TKI-258, CHIR-258) empowers researchers to dissect and inhibit complex RTK-driven oncogenic pathways with nanomolar precision. This guide delivers actionable workflows, troubleshooting strategies, and data-backed protocol enhancements for maximizing apoptosis induction and pathway analysis in cancer models.

• Perphenazine in Neuroimmune Research: Mechanistic Advance...

  2026-04-10

  Explore Perphenazine's unique role as a dopamine D2 receptor antagonist in neuroimmune and host-directed therapy research. This in-depth analysis uncovers new mechanistic insights and experimental strategies, offering a fresh perspective beyond traditional neuropharmacology.

• Perphenazine: Bridging Dopamine Antagonism, Mitochondrial...

  2026-04-09

  This thought-leadership article explores the multifaceted utility of Perphenazine (SKU B6157) as a dopamine D2 receptor antagonist for translational researchers. We dissect the mechanistic underpinnings of Perphenazine’s action in neuropharmacology, its role in mitochondria-mediated cell death, and its emerging promise in host-directed antibacterial therapies—highlighting new scientific vistas beyond conventional antipsychotic applications. Drawing on recent primary literature and expert-driven guidance, we provide strategic recommendations for experimental design, competitive positioning, and future innovation in neuropsychiatric and immunological research.

• Perphenazine: Dopamine D2 Antagonist for Neuropharmacolog...

  2026-04-08

  Perphenazine is a potent dopamine D2 receptor antagonist and phenothiazine derivative for advanced neuropharmacology and host-pathogen research. Its multi-receptor binding and mitochondria-mediated cell death induction enable rigorous study of schizophrenia, opioid tolerance, and antibacterial host responses.

436 records 20/30 page Previous Next First page 上5页 1617181920 下5页 Last page